SOX3

Across TCGA pan-cancer cohorts, SOX3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SOX3 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SOX3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SOX3 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

LUAD, CHOL, and SKCM are the cancer types where SOX3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.230	0.680	.001	30	view →
CHOL	OS	Median	All	0.019	0.800	<.001	24	view →
SKCM	OS	Median	III,IV	0.239	0.708	.003	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	DFS	Median	II,III,IV	0.887	0.374	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SOX3–LUAD (DFS)

Open the LUAD breakdown →